GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014 by Heifetz, Alexander et al.
GPCR structure, function, drug discovery and crystallography:
report from Academia-Industry International Conference (UK
Royal Society) Chicheley Hall, 1-2 September 2014
Heifetz, A., Schertler, G. F. X., Seifert, R., Tate, C. G., Sexton, P. M., Gurevich, V. V., ... Biggin, P. C. (2015).
GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International
Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. Naunyn-Schmiedeberg's archives of
pharmacology, 388(8), 883-903. DOI: 10.1007/s00210-015-1111-8
Published in:
Naunyn-Schmiedeberg's archives of pharmacology
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
©The Author(s) 2015.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
MEETING REPORT
GPCR structure, function, drug discovery and crystallography:
report from Academia-Industry International Conference
(UK Royal Society) Chicheley Hall, 1–2 September 2014
Alexander Heifetz & Gebhard F. X. Schertler & Roland Seifert & Christopher G. Tate &
Patrick M. Sexton & Vsevolod V. Gurevich & Daniel Fourmy & Vadim Cherezov &
Fiona H. Marshall & R. Ian Storer & Isabel Moraes & Irina G. Tikhonova &
Christofer S. Tautermann & Peter Hunt & Tom Ceska & Simon Hodgson &
Mike J. Bodkin & Shweta Singh & Richard J. Law & Philip C. Biggin
Received: 16 January 2015 /Accepted: 24 February 2015 /Published online: 14 March 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract G-protein coupled receptors (GPCRs) are the targets
of over half of all prescribed drugs today. The UniProt database
has records for about 800 proteins classified as GPCRs, but
drugs have only been developed against 50 of these. Thus, there
is huge potential in terms of the number of targets for new
therapies to be designed. Several breakthroughs in GPCRs
biased pharmacology, structural biology, modelling and scoring
have resulted in a resurgence of interest in GPCRs as drug
targets. Therefore, an international conference, sponsored by
the Royal Society, with world-renowned researchers from in-
dustry and academia was recently held to discuss recent prog-
ress and highlight key areas of future research needed to
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accelerate GPCR drug discovery. Several key points emerged.
Firstly, structures for all three major classes of GPCRs have
now been solved and there is increasing coverage across the
GPCR phylogenetic tree. This is likely to be substantially en-
hanced with data from x-ray free electron sources as they move
beyond proof of concept. Secondly, the concept of biased sig-
nalling or functional selectivity is likely to be prevalent in many
GPCRs, and this presents exciting new opportunities for selec-
tivity and the control of side effects, especially when combined
with increasing data regarding allosteric modulation. Thirdly,
there will almost certainly be some GPCRs that will remain
difficult targets because they exhibit complex ligand dependen-
cies and havemanymetastable states rendering them difficult to
resolve by crystallographic methods. Subtle effects within the
packing of the transmembrane helices are likely to mask and
contribute to this aspect, which may play a role in species de-
pendent behaviour. This is particularly important because it has
ramifications for how we interpret pre-clinical data. In summa-
ry, collaborative efforts between industry and academia have
delivered significant progress in terms of structure and under-
standing of GPCRs and will be essential for resolving problems
associated with the more difficult targets in the future.
Keywords GPCRs, G-protein coupled receptors .β2AR,
β2-adrenergic receptor . GLP-1, Glucagon-like peptide-1
receptor . CCK2R, cholecystokinin receptor-2 . δ-OR,
delta-opioid receptor . CRF1, corticotropin releasing factor
receptor 1 . CXCR1, CXCR2, CCR4 and CCR5, chemokine
receptors . 5-HT2B and 5-HT2C, human 5-hydroxytryptamine
receptors 2B and 2C, respectively . H1, histamine receptor 1 .
hM3R, humanmuscarinicM3 receptor . Dopamine D2
receptor .α1BAdrenergic receptor . T4L, T4-lysozyme .
BRIL, apocytochrome b562RIL . XFELs, x-ray free electron
lasers . SDM, site-directedmutagenesis .MD,molecular
dynamic simulations . 3D, three-dimensional . 7TM,
seven-transmembrane domain . TM, trans-membrane helix .
ECL,extracellular loop .HGMP,hierarchicalGPCRmodelling
protocol . GLAS, GPCR-likeness assessment score . ProS,
pairwise protein similaritymethod . PDB, Protein Data Bank
Introduction
The Royal Society Academia-Industry International Confer-
ence 2014 focussed on the topic of ‘GPCR Structure, Func-
tion, Drug Discovery and Crystallography’ and was held on
September 1–2 in Chicheley Hall, UK. This conference
brought together 20 renowned experts in GPCR research
and drug discovery spanning Europe, Australia and North
America. Approximately half of the attendees were from aca-
demia and half from industry (see Fig. 1).
GPCRs are a large family of integral membrane proteins
that have enormous physiological and biomedical importance.
Since GPCRs are involved in mediating cell signalling pro-
cesses, they are implicated inmany diseases and are the targets
of numerous therapeutic drugs. This renders GPCRs one of
the most important classes of current pharmacological targets.
This is borne out by the fact that 60% of all prescription drugs
today target GPCRs (Schöneberg et al. 2004), developed for
just 50 established GPCR targets out of the 800 known mem-
bers of the gene family. The importance of GPCRs was re-
cently highlighted with the Nobel Prize for Chemistry 2012
being awarded to two eminent GPCR researchers, Prof. Brian
Kobilka (Stanford University, CA, USA) and Prof. Robert
Lefkowitz (Duke University, NC, USA). There remains an
ongoing need to better understand the interplay between struc-
ture and function of these receptors to advance our scientific
knowledge and capacity to more effectively harness therapeu-
tic capabilities. As a result, GPCR crystallography and model-
ling are rapidly expanding. However, there is still a sizeable
gap between ongoing academic research and the needs of the
pharmaceutical industry. A major reason for this is that aca-
demic and industrial scientists have too few productive oppor-
tunities to meet and interact, particularly to establish cross-
discipline collaborations. The intimate atmosphere of such a
small conference provided a unique opportunity to stimulate
the generation of new networks and partnerships between ac-
ademia and industry, and to promote current GPCR research
and its applications to drug discovery. The invitation of scien-
tists representing structural biology, protein engineering, phar-
macology as well as computational and medicinal chemistry
provided an interdisciplinary core to enable fruitful discussion
and debate.
Many of the presentations stressed the importance of col-
laboration. For example, Prof. Schertler pointed out that dur-
ing 18 years at the MRC Lab in Cambridge, he had a contin-
uous string of collaborations with industry partners from small
and large Pharma that created a very valuable network of
complementary expertise. This collaborative network led to
breakthroughs in the expression and purification of difficult
membrane protein targets, and later this network was an im-
portant ingredient in the formation of the drug discovery spin
out company Heptares Therapeutics. Several of Prof.
Schertler’s earlier industry partners became the drivers of this
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GPCR-oriented company with their expertise on target selec-
tion, business models and intellectual property (IP)
complemented perfectly the expertise of the MRC academic
partners. The spin out company has in the meantime grown
from three post docs to about 80 people, and it is able to tackle
the most difficult GPCR targets with resources that would
otherwise not have been accessible in Europe from any
funding agency.
The basis of good industry academia collaboration is a
clear agreement about the goals of the collaboration. Very
often selecting a pre-competitive goal allows the academic
partner to fully publish the results and gives the industry part-
ner a significant edge in accessing emerging technologies. The
example of Heptares Therapeutics illustrates that a spin out
company can generate resources that would neither be avail-
able inside a company or from public funding agencies. If the
spin out is able to reach milestones and refinance, then it can
become a powerful tool to drive the application of new tech-
nology and lead to a change in the research culture in industry.
Most ventures between academia and industry are depen-
dent on track record and trust. Individuals have to commit to a
longer-term perspective, which is aimed at changing the sci-
entific landscape. This scientific environment is essential for
large companies that exist and are established to be able to
recruit an excellent workforce and for small companies to pick
up competitive innovation. In multinational companies, the
academic and technology environment can start to dictate
the location of departments inside a large organisation. From
this follows that for a stable business development, the aca-
demic environment is as essential to the company as the in-
house research activities.
One of the most significant advances in previous years has
been the structural advances, both in terms of stabilising protein
conformational states to make them more amenable to x-ray
crystallography, but also in new technology such as x-ray free
electron lasers which have the potential to accelerate structural
biology not just for GPCRs but for many integral membrane
protein drug targets. A significant portion of the meeting
discussed these advances and also how they had been used in
recent drug-discovery programs within both industry and aca-
demia. Another focus in recent times has been the concept of
‘ligand bias’. It has become clear that individual GPCRs can
exist in multiple receptor conformations and can elicit numer-
ous functional responses, both G protein- and non-G protein-
mediated. This has led to the discovery that different ligands
can stabilise distinct subsets of receptor conformations that can
‘traffic’ stimulus to diverse functional outputs with varying
prominence, a concept referred to as biased signalling (also
known as functional selectivity, stimulus bias or ligand-
directed signalling). In principle, biased signalling can result
in the development of more efficacious and safer drugs, but
there are some unresolved questions regarding the best system
in which to assess these aspects. The structural information
alongside the realisation of biased signalling has also been ex-
plored with in silico modelling, and it was demonstrated at the
meeting that this can give very useful insight into underlying
properties of signalling control. The final section of the meeting
focussed on how to best resolve problems in the future, includ-
ing modelling processes at a higher level. In the following
sections, we expand on these discussions in more detail.
Developments in GPCR crystallography
It is apparent from numerous studies that the stability of the
GPCR-ligand complex in detergent solution is an important
Fig. 1 Attendees of the
conference (listed from left to
right): front row—Isabel Moraes,
Fiona Marshall, Gebhard
Schertler and Patrick Sexton;
second row—Shweta Singh, Irina
Tikhonova, Tom Ceska, Roland
Seifert, Simon Hodgson, Daniel
Fourmy and Alexander Heifetz;
back row—Ian Storer, Mike
Bodkin, Vadim Cherezov,
Christofer Tautermann,
Christopher Tate, Vsevolod
Gurevich and Peter Hunt.
Chicheley Hall itself can be seen
in the background (the
photograph was taken by Richard
Law)
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parameter that will dictate the success of any crystallisation
trials (Tate 2012). Although high thermostability alone does
not guarantee the formation of diffraction-quality crystals, if
the GPCR-ligand complex is too unstable, then crystals may
not form or, if they do, they may diffract only poorly. The
majority of GPCR structures have been determined from crys-
tals of the receptor bound to a high-affinity antagonist, which
usually binds with Kd or Ki values in the range of 10 pM to
10 nM. However, if a ligand binds to a receptor only with low
affinity and/or the receptor is unstable in detergent, then it may
still be possible to obtain a structure if the receptor is
thermostabilised. A method developed to thermostabilise
GPCRs uses systematic scanning mutagenesis coupled to a
thermostability assay performed on the detergent-solubilised
mutant receptors to identify specific thermostabilising muta-
tions (Tate 2012). Each mutation usually imparts 1–3 °C im-
provement in thermostability to the receptor, although the
most highly stabilising mutation found improved thermosta-
bility of the agonist-bound conformation of the adenosine A2A
receptor by 14 °C. Once the single thermostabilising muta-
tions have been identified, then the best thermostabilising mu-
tations can be combined to make an optimally stable receptor
(Shibata et al. 2013). The methodology has been applied to
many different GPCRs, in either an antagonist-bound confor-
mation or an agonist-bound conformation, which have been
subsequently crystallised and their structures determined. The
most recent structure (Miller-Gallacher et al. 2014) was a 2.1-
Å resolution structure of the β1-adrenergic receptor (β1AR)
bound to cyanopindolol (see Fig. 2) and the crystals grown in
lipidic cubic phase, although without requiring fusions of the
receptor to either T4-lysozyme (T4L) or apocytochrome
b562RIL (BRIL). The structure showed the presence of an
intramembrane sodium ion that was in the identical position
to the intramembrane sodium ion in the adenosine A2A recep-
tor that is known to act as an allosteric antagonist. In contrast,
the Na+ ion in β1AR does not appear to affect the transition
between the inactive and active states of the receptor.
A significant advantage of the thermostabilised receptors is
their use in drug discovery, which for the first time opens up
the opportunities for structure-based drug design (Congreve
et al. 2014). The thermostabilised receptors are readily puri-
fied and crystallised on a routine basis, which facilitates co-
crystallisation with fragments and lead compounds. This was
recently demonstrated for the β1AR where a fragment screen
performed by surface plasmon resonance (SPR), followed by
minimal hit optimisation, produced nM-affinity antagonists
with novel scaffolds that were readily co-crystallised with
the receptor (Christopher et al. 2013). The thermostabilisation
of GPCRs is a central platform in Heptares Therapeutics,
resulting in numerous crystal structures.
Another structural approach gaining momentum is the ap-
plication of x-ray free-electron lasers (XFEL) to GPCRs.
Structural studies of GPCRs, and other biomedically relevant
membrane proteins and complexes, are hampered by chal-
lenges related to growing sufficiently large crystals capable
of withstanding radiation damage and yielding high-
resolution data at synchrotron sources. The recent introduction
of a new generation of x-ray sources, x-ray free electron lasers
(XFELs), producing ultra-bright pulses of coherent x-rays
with an ultrashort duration, holds the promise to advance our
Fig. 2 Crystal structures of
β1AR bound to novel
chemotypes developed by
fragment screening and hit
optimisation. Structures of the
ligand binding pocket are
depicted with only portions of
selected transmembrane helices
(H3, H5, H6 and H7) shown with
the side chains (green) and
ligands (yellow) depicted in
sticks: a cyanopindolol, PDB
code 2VT4; b compound 19,
PDB code 3ZPQ; c compound 20,
PDB code 3ZPR—figure adapted
from the publication (Christopher
et al. 2013)
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understanding of structure and function of these challenging
targets.
A novel approach using a membrane mimetic gel-like ma-
trix known as lipidic cubic phase (LCP) for growth and deliv-
ery of membrane protein microcrystals for data collection by
serial femtosecond crystallography (SFX) at XFELs (Liu et al.
2013) was described. Microcrystals are delivered to the inter-
section point with an XFEL beam in random orientations
using a specially designed LCP injector (Weierstall et al.
2014). The injector allows adjusting LCP flowrate in a wide
range to match the XFEL pulse repetition rate and, thus, min-
imises crystal consumption. LCP-SFX uses highly intense
sub-50-fs XFEL pulses to overcome radiation damage and
collect room temperature high-resolution data from sub-
10-μm crystals. Protein consumption is reduced by two to
three orders of magnitude compared to previously used liquid
injectors, making the LCP-SFXmethod attractive for structur-
al studies of challenging membrane and soluble proteins, and
their complexes (see Fig. 3) (Liu et al. 2014a, Liu et al.
2014b).
Results demonstrating the great utility of this approach
were highlighted at the meeting. They included the structure
of the human delta-opioid receptor bound to a bi-functional
peptide ligand (Fenalti et al. 2014), the structure of a major
GPCR signalling complex (unpublished data) and the first
novel GPCR structure solved entirely by the LCP-SFX ap-
proach (unpublished data). In the future, this method could
lead to the development of an efficient GPCR structure-
based drug design pipeline by removing the major obstacles,
such as the difficulties in preparation of large amounts of
homogeneous and stable protein and growing sufficiently
large crystals for a large number of different protein-ligand
complexes. Another advantage of XFELs is the ability to
freeze protein motion in time and obtain structures of unstable
intermediates, advancing our knowledge about the signal
transduction mechanism in GPCRs.
It was also noted that there are many signalling complexes
in the cell that have component parts that have some flexibility
as part of the structure necessary for function. Where these
structures are difficult to stabilise, crystallisation is often prob-
lematic. Quite often crystallography can stumble because only
very small crystals are attainable, with very weak diffraction,
and this can be due, in part, to some partial disorder in a
biologically relevant part of the molecule. The crystallograph-
ic solution up to now has been to delete or modify the flexible
regions of the protein in order to create constructs that are
more ordered so that crystals of significant size could be
grown. With diffraction from microcrystals now possible,
the structures of these more challenging biological assemblies
are within reach.
Improvements in the understanding of GPCR function
In terms of function, the human β2-adrenergic receptor
(β2AR) is probably the best-studied GPCR at the molecular,
cellular and physiological level (Seifert 2013). The β2ARwas
of critical importance for the development of current models
Fig. 3 Schematic summary
illustrating serial femtosecond
crystallography of GPCRs with
using lipidic cubic phase for
microcrystal growth and delivery
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of receptor activation including biased signalling. Recent re-
search has also shown for this system that ligand bias can
depend on the system studied (native versus recombinant)
(Seifert 2013) and also on the (patho)physiological state
(healthy versus diseased), a feature sometimes also referred
to as dynamic bias (Michel et al. 2014). Accordingly, the
analysis of ligands at receptors such as the β2AR has become
much more complex, requiring multidimensional approaches.
Theβ2AR constitutes an important drug target; agonists for
this receptor are used for treatment of bronchial asthma and
chronic-obstructive lung disease. However, safety and
efficacy of β2AR agonists are not optimal. Most strikingly,
the use of β2AR agonists alone in asthma is associated with
increased mortality. Receptor desensitisation and activation of
deleterious non-canonical signalling pathways, i.e. pathways
different from the canonical Gs pathway, could contribute to
this situation. Moreover, specific β2AR polymorphisms may
be associated with decreased responsiveness to certain li-
gands, and the use of racemic β2AR ligands may be problem-
atic. Specifically, the distomeric (not therapeutically active)
ligands may contribute to drug toxicity (Seifert and Dove
2009).
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Based on these concerns, non-canonical signalling path-
ways, receptor polymorphisms and pure β2AR stereoisomers
were examined in a pluridimensional signal transduction ma-
trix. This matrix included studies with recombinant β2AR and
native β2AR expressed in human neutrophils (see Fig. 4).
Human neutrophils constitute a relevant cell type for inflam-
mation in bronchial asthma that can be readily isolated in
substantial numbers. In neutrophils, the β2AR exerts anti-
inflammatory effects by inhibiting chemoattractant-
stimulated superoxide radical formation. Steroisomers of
fenoterol were used as model ligands because these ligands
have already been shown to exhibit functional selectivity (Sei-
fert and Dove 2009).
In aggregate, these studies revealed that most reported li-
gands are biased towards canonical Gs signalling (Reinartz
et al. 2015). This is particularly evident for ligands with large
N-alkyl substituents, suggesting that these ligand domains,
through constrained mobility of transmembrane helices, im-
pede with coupling to Gi proteins and β-arrestin. In principle,
this pharmacological pattern of fenoterol stereoisomers should
be favourable for asthma treatment. However, the Seifert
group did not identify any ligand with bias towards Gi or β-
arrestin.
With regard to polymorphisms, 60 healthy volunteers were
studied (see Fig. 4b). From these volunteers, blood was drawn
and neutrophils were isolated. The pharmacological profile of
the β2AR with respect to inhibition of superoxide radical for-
mation was assessed. Moreover, the β2AR gene of the indi-
viduals was sequenced. Overall, substantial variability in the
pharmacological profile of the β2AR in neutrophils was not-
ed, but no association of the pharmacological β2AR profile
with a specific polymorphism emerged. Thus, at the time be-
ing, there is no evidence for the notion that β2AR polymor-
phisms can be used to optimise asthma therapy.
To summarise this aspect, our increase in knowledge of the
β2AR has resulted in a situation that renders future research
more complicated. Most importantly, it is not anymore suffi-
cient to determine a single parameter for a receptor such as Gs-
mediated adenylyl cyclase activation. Rather, multiple param-
eters have to be determined including non-canonical Gi- and
β-arrestin signalling. It is important to analyse the β2AR not
only in recombinant but also in native systems. It will also be
very informative to resolve crystal structures of the β2AR in
complex with various ligands and coupling partners to under-
stand the molecular basis of functional selectivity (Seifert and
Dove 2009).
The GLP-1 receptor represents a good model system for
studying class B receptor function (Koole et al. 2013a, b;
Wootten et al. 2013a). GLP-1 is a key incretin peptide that
promotes insulin secretion in response to nutrient ingestion,
but also has a range of other actions including preservation of
B-cell mass, reduction in gastric emptying and reduction in
appetite that make it a desirable target for treatment of type II
diabetes. Class B secretin-like receptors, like many other
GPCRs, are pleiotropically coupled to a spectrum of both G-
protein-dependent and -independent signalling pathways, and
while cAMP production is the best characterised signalling
endpoint for these receptors, physiological and therapeutic
responses are the product of the integrated signalling response
from all activated pathways. Moreover, the different contacts
that are made between distinct ligands and their respective
receptor can engender unique receptor conformations that
give rise to distinct signalling profiles. This behaviour can
be observed through differences in activation of second mes-
sengers, but also through changes to how receptors are
desensitised and down-regulated. Biased signalling is further
complicated when allosteric drugs are considered, as confor-
mational preferences of the receptor when allosteric and
Fig. 4 a Multidimensional analysis of the β2AR in native and
recombinant systems. Study design. The concept of functional
selectivity requires that a given GPCR is analysed in multiple different
assays. GPCR-Ga fusion proteins ensure a defined 1:1 stoichiometry of
receptor and G-protein and allow analysis of GDP/GTP turnover,
measured in the GTPase activity assay, and effector system activation,
measured in the adenylyl cyclase (AC) assay, with high sensitivity. The
measurement of β-arrestin recruitment is accomplished in HEK cells
stably transfected with fusion proteins of the β2AR linked to a
luciferase fragment and β-arrestin linked to the complementary
luciferase fragment. Upon binding of an agonist, β-arrestin binds to the
GPCR, and luciferase activity is reconstituted. Human neutrophilic
granulocytes constitute a physiologically relevant model system for the
β2AR. In these cells, the β2AR couples to AC (isoform 9), resulting in an
increase in the second messenger cAMP. The β2AR inhibits formyl
peptide receptor (FPR)-mediated activation of the neutrophilic NADPH
oxidase (NOX) that generates reactive oxygen species (ROS). FPR-
mediated NOX activation is inhibited by the β2AR. It is generally
assumed that this inhibition is mediated via cAMP, but an increasing
number of studies indicate that the inhibition is actually cAMP
independent. b Functional and genetic analysis of β2AR
polymorphisms in 60 healthy volunteers. Study design. A major goal of
current pharmacological research is the development of individualised
pharmacotherapy that takes into account individual genetic
polymorphisms. At the level of GPCRs, very little research has been
performed in this field so far. Therefore, as a model receptor, the β2AR
was analysed because for this GPCR several polymorphisms are already
known, but assignment of specific polymorphisms to defined disease
entities is controversial. After obtaining consent from volunteers and
completing a questionnaire, a small sample of blood (4–8 ml) was
drawn from healthy male and female subjects. A fraction of the blood
was used to sequence the β2AR gene to identify known (and unknown)
β2AR polymorphisms. The remainder of the blood was used to isolate
human neutrophils and assess the pharmacological profile of the β2AR
with several standard ligands according to the signalling paradigm shown
in (a). Ligands were characterised with regard to potency and efficacy.
The data sets have now been completed. The pharmacological profile of
each individual was assessed several times. Currently, data are analysed
in multiple ways. Specifically, the impact of specific β2AR
polymorphisms on the pharmacological profile is assessed.
Additionally, the impact of sex, age, smoking and allergy history on
β2AR pharmacology is evaluated. The study fills a gap in the field
because it provides data on the pharmacological properties of GPCR
polymorphisms in a physiologically relevant context. The results of the
study will be submitted for publication to a peer-reviewed journal in
spring 2015
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orthosteric (endogenous ligand) sites are co-occupied may be
different than when either site is individually occupied. Biased
signalling is particularly relevant to receptor systems that have
multiple endogenous ligands, and where exogenous mimetics
are used clinically, as is often seen with class B receptors.
Clear (ligand-directed) bias for both peptides and small
molecule agonists of the GLP-1 was demonstrated (Koole
et al. 2013a, b), and this is consistent with earlier studies of
pituitary adenylyl cyclase-activating polypeptide type 1 recep-
tor (PACAPR) receptors and unclassified class B members
like hCTRs, suggesting that this is likely to be a common
feature of agonist activation of class B receptors. Transmem-
brane helical packing and conformational transition involved
in receptor activation are assumed to involve key hydrogen
bond networks formed around polar residues in the transmem-
brane helices.
The importance of conserved polar residues in class B re-
ceptors at the GLP-1 receptor has been recently studied
(Koole et al. 2013a; Wootten et al. 2013b). This work has
revealed networks of interaction that differentially contribute
to global receptor activation and biased signalling. In particu-
lar, there appear to be two key interaction networks, one at the
base of the receptor that may serve a similar role to the
D[E]RY motif in class A receptors to maintain an inactive
state; the second is located in the mid-region of the helical
core and plays a critical role in pathway specific signalling,
in a ligand-dependent manner. Mutation of residues within the
central network has identified differences in how ligands
propagate activation transition for individual signalling path-
ways and that distinct ligands utilise only subsets of the net-
work for signal propagation providing initial insight into mo-
lecular mechanisms for biased signalling.
The concept of biased signalling has also been explored in
the cholecystokinin receptor-2 (CCK2R, which also binds the
digestive hormone gastrin) (Magnan et al. 2011, 2013) and is a
GPCR for which pharmaceutical companies and academic
laboratories have successfully developed non-peptide ligands,
mostly antagonists. Since CCK2R is a potential target in sev-
eral pathologies of the central nervous system (anxiety, panic
attacks), of the gut (peptic ulcer disease) and of neuroendo-
crine cancers, the effects of a series of such ligands on stimu-
lation of phospholipase-C and as well as on recruitment of
non-visual arrestins and stimulation of receptor internalisation
have been studied (see Fig. 5).
Several ligands stimulating phospholipase-C with effica-
cies reaching up to 50 % of that of CCK but which were
inefficient to stimulate β-arrestin1/2 recruitment and receptor
internalisation have been identified (Magnan et al. 2011). The-
se ligands, which were initially considered as full antagonists
at the CCK2R, are therefore more accurately described as an-
tagonists on the β-arrestin-dependent signalling pathway of
this receptor, but are partial agonists of the G-protein-
dependent signalling pathway.
Extending these studies to ligands that are antagonists of G-
protein-dependent pathways, it was discovered that the antag-
onist termed GV150013X (N-(+)-[1-(Adamant-1-ylmethyl)-
2 ,4 -d ioxo -5 -pheny l -2 ,3 ,4 ,5 - t e t r ahydro -1H -1 ,5 -
benzodiazepin-3-yl]-N′-phenylurea) (see Fig. 5) could not in-
hibit β-arrestin1/2 recruitment and CCK-induced CCK2R
internalisation (Magnan et al. 2013). Schild plot analysis of
antagonist activity of GV150013X on CCK-induced phos-
pholipase-C activation indicated that this molecule competi-
tively inhibited the CCK effect. This information led the team
to dock GV150013X in the orthosteric binding site of the
modelled CCK2R, which had been previously validated by
site-directed mutagenesis. The docking study predicted that
the absence of effect of GV150013X on CCK2R recruiting
β-arrestins was due to the presence of a bulky adamantane
Fig. 5 Schematic representation
of the CCK2R which can adopt
two distinct conformational states
upon CCK activation. The
CCK2R
G state couples to
phospholipase-C activation and
the CCK2R
β state recruits β-
arrestins. This figure also shows
that GV150013X, a competitive
antagonist on CCK2R
G, is
inefficient to inhibit recruitment
of β-arrestins by CCK2R
β
because of steric hindrance at the
orthosteric binding site
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moiety in the ligand. GV150013X competitively inhibited
CCK-induced G-protein-dependent pathway whereas it was
inefficient on the β-arrestin-dependent pathway. These data
suggested that the CCK2R could adopt two distinct conforma-
tions upon CCK activation and these two conformations are
distinguishable at the binding site level. Fourmy’s lab there-
fore performed a site-directed mutagenesis study of the
CCK2R orthosteric binding site with a focus on amino acids
presumably in contact with the adamantane moiety of
GV150013X. In parallel, the team synthesised an analogue
of GV150013X in which the adamantane moiety was
substituted by a methyl group: 1-(2,3,4,5-tetrahydro-1-meth-
yl-2,4-dioxo-5-phenyl-1H-benzo[b][1,4]diazepin-3-yl)-3-
phenylurea, termed GV-CH3. Pharmacological studies with
CCK2R mutants and with GV-CH3 consistently demonstrated
that the prediction of modelling and docking study was cor-
rect: the absence of effect of GV150013X on recruitment ofβ-
arrestins to the CCK2R was due to a steric hindrance within
the binding site which impedes binding of the antagonist
(Magnan et al. 2013).
Overall, this area of research shows how pharmacological
analysis of GPCR signalling combined with molecular model-
ling of GPCRs and chemistry of ligands can be used to analyse
the origin of biased signalling. Such a strategy together with
forthcoming determination of GPCR structures in complex
with various signalling proteins (G proteins, β-arrestins)
opens the possibility of rational drug design of biased ligands.
One of the biased-agonism pathways involves arrestins,
and they themselves present an alternative line of investiga-
tion. Arrestins specifically bind active phosphorylated
GPCRs, precluding further G protein activation and channel-
ling the signalling to G-protein-independent pathways
(Gurevich and Gurevich 2006). Based on the elucidation of
an arrestin structure and key functional elements, special
arrestins to channel cell signalling in a desired direction were
constructed (Gurevich and Gurevich 2012). Enhanced
phosphorylation-independent arrestin mutants were designed
by disrupting key stabilising intra-molecular interactions that
hold arrestins in a basal conformation (Gurevich and Gurevich
2012). Enhanced arrestin-1 was shown to compensate for the
defects of rhodopsin phosphorylation in vivo, prolonging the
survival of mutant rod photoreceptors, improving their light
sensitivity and speeding up photoresponse recovery (Song
et al. 2009). While the compensation with the first-
generation enhanced mutant was only partial, new more pow-
erful phosphorylation-independent forms of arrestin-1 hold
promise for a better compensation (Vishnivetskiy et al.
2013). In rod photoreceptors, rhodopsin-specific arrestin-1 is
the prevalent form, so it is clear that one needs to target this
subtype to compensate for disease-causing defects of rhodop-
sin phosphorylation.
However, activating mutations in many GPCRs underlie
various human disorders (Schöneberg et al. 2004). Since the
two non-visual arrestins are fairly promiscuous, interacting
with hundreds of GPCR subtypes, and most cells express 5–
25 different GPCRs, only one of which is a mutant, to use a
compensational approach, one needs receptor-specific non-vi-
sual arrestins. To this end, the elements of non-visual arrestins
that determine their receptor preference were identified
(Vishnivetskiy et al. 2011), and on the backbone of the most
promiscuous non-visual subtype, arrestin-3, mutants with
high (>50-fold) receptor specificity were created (Gimenez
et al. 2012). This finding showed that targeting individual
receptors with engineered non-visual arrestins is feasible.
Arrestins interact with numerous partners, organising multi-
protein complexes and recruiting them to particular sub-
cellular compartments (Gurevich and Gurevich 2014a, b).
This creates the potential of constructing signalling-biased
arrestins that activate or inhibit certain pathways without af-
fecting others. Recently, Gurevich and colleagues designed an
arrestin-3 mutant that acts as a silent scaffold: it binds all
kinases in the c-Jun N-terminal kinase (JNK) activation cas-
cade, but does not promote its phosphorylation (Breitman
et al. 2012). This mutant was shown to act in a dominant-
negative fashion, suppressing JNK activation in the cell
(Breitman et al. 2012). Multi-functionality of arrestins sug-
gests that parts acting on particular pathways can be separated
and used to modify cell signalling. Indeed, a small element of
arrestin-3 that acts as a mini-scaffold, promoting JNK activa-
tion in vitro and in cells, has been identified (Zhan et al. 2014).
Anti-proliferative activity of this element can be used for ther-
apeutic purposes. Since arrestins play a role in numerous sig-
nalling pathways, targeted mutagenesis can yield arrestin-
based molecular tools to tell the cell what to do in a language
it cannot disobey (Gurevich and Gurevich 2014a, b).
Challenges and solutions for GPCR drug discovery
Despite many examples of successful marketed drugs that
modulate the function of GPCRs, there remain a large number
of potential therapeutically relevant GPCRs that are regarded
as difficult to drug effectively. Methods used to analyse the
GPCR’s ligand binding sites with a view to designing ligands
were reviewed and included a discussion on the importance of
water molecules for mediating interactions between ligands
and receptor.
Heptares use their StaR® technology to generate
thermostabilised GPCRs which can be used for biophysical
studies, fragment screening and determination of x-ray struc-
tures. Examples were presented from different GPCRs show-
ing that the most potent ligands act to displace high energy or
‘unhappy’ waters deep within binding pockets. Water mole-
cules can contribute to both ligand selectivity and kinetics. An
overview of class B and class C structures recently solved at
Heptares (see Fig. 6) was also presented. The corticotropin
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releasing factor receptor 1 (CRF1) x-ray structure identified a
novel allosteric binding pocket deep within the transmem-
brane domain and illustrated why finding ligands for the
orthosteric pocket has been challenging. The structure of class
C metabotropic glutamate 5 receptor (mGlu5) was shown and
provided an explanation for the tight structure-activity rela-
tionships (SARs) and pharmacology mode switching which
have been observed for this receptor. The conclusions were
that structure-based design could in theory now be applied
more broadly across the GPCRome.
Antihistamines are one of the most well-studied drugs (Si-
mons and Simons 2011). Indeed, it is nowmore than a century
since the discovery of histamine as an important biogenic
substance and more than 50 years since the production of
the first antihistamine drugs (e.g. chlorpheniramine, diphen-
hydramine, hydroxyzine). H1R antagonists (antihistamines)
are widely used in the treatment of a broad range of allergic
diseases like rhinitis, conjunctivitis, urticaria and non-allergic
disorders like pruritus and insomnia (Simons and Simons
2011). The first generation of H1R antagonists that had been
introduced in the period of 1942–1980 demonstrated
considerable side effects. Poor selectivity for the H1R and
the ability to cross the blood–brain barrier (BBB) interfering
with the histaminergic transmission (sedation) were among
the most unwanted side effects. Recent studies have shown
an increase in the number of allergic diseases, currently affect-
ing more than 30 % of the world population (Qin 2007).
Hence, there is an urgent need for more effective and safe
anti-allergic drugs. The second-generation H1R antagonists,
introduced in the early 1980s, had notable advantages such
as being significantly more selective and non-sedating due to
the lack of the ability to cross the BBB. These second-gener-
ation, non-sedating H1R antagonists have been widely used in
the treatment of allergic conditions but still demonstrated
some cardiotoxic side effects, e.g. induction of torsades-de-
pointes arrhythmias. This has recently led to the development
of third-generation H1R antagonists where both sedative and
cardiovascular side effects were addressed (Oppenheimer and
Casale 2002; Canonica and Blaiss 2011).
The crystal structure of the first-generation H1R antagonist
doxepine bound to H1R was solved in 2011 (Shimamura et al.
2011). Doxepine has been associated with a large number of
different side effects that can be rationalised by its lack of H1R
selectivity and being a potent binder of H2R, some members
of muscarinic, serotonic and α-adrenergic GPCR subfamilies
and also of some protein kinases. Due to the lack of doxepine
selectivity, the need for additional crystal structures of H1R
bound to second and third generation of antihistamines that
will rationalise the selectivity cannot be overestimated.
Dr. Moraes reported for the first time the solution of two
additional holo H1R crystal structures bound to the highly
selective second- and third-generation H1R antagonists:
Cetirizine (Gillard et al. 2002) and Fexofenadine (Sharma
et al. 2014), respectively (unpublished data; see Fig. 7).
Cetirizine and Fexofenadine are about 600-foldmore selective
for H1R compared with a wide panel of GPCRs and ion chan-
nels (Gillard et al. 2002). This work has resulted from collab-
oration between Evotec Ltd and the Membrane Protein Lab-
oratory (MPL—Imperial College London).
These new structures provide insights into potency and
selectivity, the key challenges for the design of new generation
of H1R antagonists and provide a significant contribution to
potentially aid computational guided structure-based drug dis-
covery of new antihistamine drugs targeting H2, H3 and H4
receptors where crystal structures are still absent.
Structural information in conjunction with careful model-
ling can provide greater insight into the location and function-
al relevance of druggable binding locations including both
orthosteric and allosteric sites. Several recent structural publi-
cations have provided greater clarity on the binding modes
and kinetics of existing drugs in both orthosteric sites, such
as bronchodilator tiotropium binding to muscarinic M3 recep-
tor (Tautermann et al. 2013), and allosteric binding sites, such
as anti-viral maraviroc which acts as a negative allosteric
Fig. 6 Crystal structure of the class C mGlu5-mavoglurant receptor
(Bennett et al. 2014) complex with CP-376395 from the class B
receptor CRF1 and overlays of a selection of ligands from class A
receptor structures present in the PDB. The observed ligand binding
positions demonstrate the spectrum of binding modes across GPCR
classes ranging from extracellular orthosteric to deeper intracellular
allosteric sites
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modulator of chemokine receptor CCR5 (Kruse et al. 2012;
Tan et al. 2013). Provision of knowledge of this type should
begin to assist in design of more subtype selective ligands,
especially when combined with leading edge computational
techniques such as homology modelling (Storer et al. 2014)
and molecular dynamic simulations.
An area where increased structural knowledge could be
especially impactful is in the improved design and optimisa-
tion of selective ligands. Selectivity between subfamily mem-
bers of GPCRs has proved essential yet challenging in some
instances, a notable example being the design of highly selec-
tive serotonin (5-HT) 5-HT2C-receptor agonists (see Fig. 8)
(Monck and Kennett 2008).
Agonism of the 5-HT2C receptor has therapeutic implica-
tions in a number of important disease areas including CNS
disorders and obesity. However, the design of ligands that are
selective over agonism of the closely related 5-HT2B receptor,
which has been linked with irreversible heart valvulopathy,
has proved highly challenging (Storer et al. 2014). Further-
more, ligand-protein interaction features that lead to receptor
agonism versus antagonism versus inverse agonism are not
well understood despite numerous examples of subtle ligand
structural changes driving pronounced differences in function-
al efficacy of GPCRs (Storer et al. 2014).
This is further complicated in instances where the same
ligand exerts a different functional effect in different isoforms
of the same receptor. This has been demonstrated by differen-
tial effects in the human isoform compared to the equivalent
preclinical species receptors, hampering both in vivo efficacy
and safety studies. An illustrative example is the histamine H4
receptor antagonist program where an inverse agonist of the
human H4-receptor was a partial agonist of rat and an
antagonist of dog H4 receptor, complicating the interpretation
of preclinical in vivo studies (Mowbray et al. 2011). There-
fore, a greater appreciation for the structural basis for these
effects could ultimately assist in prediction and systematic
avoidance of similar issues in future programs.
Biased signalling is of current interest to both academia and
the pharmaceutical industry based on the hypothesis that it
could provide improved therapeutic benefit whilst avoiding
undesirable activities that unbiased signalling of certain recep-
tors has historically caused (Tautermann 2014). This has pro-
vided motivation to revisit some GPCR targets that were pre-
viously either poorly drugged or deemed undruggable due to
lack of therapeutic index over adverse events (Correll and
McKittrick 2014). However, despite advances in biology
and chemistry providing assay methods to measure bias and
clear examples of biased ligands emerging, a deeper structural
understanding of protein conformational changes and interac-
tions that lead to differential receptor signalling is still in its
infancy but clearly of keen interest to the medicinal chemistry
community (Violin et al. 2014).
Chemokine receptors are additional examples of ‘difficult’
GPCR targets, which usually have multiple peptide agonist
ligands. CCR4 appears to have three different binding sites
for peptide agonist and small molecule ligands (see Fig. 9).
Complexity was further demonstrated in that two classes of
chemically distinct small molecule ligands bind to different
sites, both of which are allosteric modulators and also display
different functional signalling (Procopiou et al. 2013; Slack
et al. 2013; Ajram et al. 2014). Furthermore, one small mole-
cule ligand site appears to be intracellular.
This complex picture of CCR4 resulted from extensive
chemistry and pharmacological studies, and in hindsight it is
Fig. 7 Crystal structure of H1R
bound to highly selective second-
and third-generation
antihistamines: Cetirizine (left)
and Fexofenadine (right)
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clear why ‘traditional’ screening approaches such as binding
or whole cell studies did not clearly identify the range of
different ligands and sites. In one such screening approach,
it was rationalised that the intracellular ligand binding site
(helix 8) in CCR4 was likely modified owing the proximal
chemical modification required in the commonly used FLIPR
format.
Other examples of ‘difficult’ GPCR ligands include hista-
mine dual H1R and H3R antagonists. Whilst the individual
targets are well tractable individually, the design of single
molecules that ‘fit’ and potently antagonise both receptors,
and have added properties of broader selectivity and intranasal
or oral drug properties, is extremely time consuming and chal-
lenging. (Procopiou et al. 2011) (see Fig. 10).
Thus, structurally enabled approaches to ‘difficult’ GPRC
targets should improve the tractability for chemistry by the
direct identification of novel multiple ligand binding sites
and subsequent chemical optimisation of small molecule li-
gands to drugs. This is an opportunity for drug discovery in a
class of GPCR targets not easily accessible by previous
methods.
Whilst many GPCR targets are chemically tractable
resulting in multiple ligands and successful drugs, there are
still many GPCR targets which are not amenable to ‘tradition-
al’ approaches, such as focussed or high throughput screening,
or where the natural ligands are unsuitable starting points for
the design of oral drugs owing to their properties (e.g. large,
lipophilic or peptidic).
Fig. 8 Modelling of binding and
activation of 5-HT2C (Storer et al.
2014) receptor by pyrimido[4,5-
d]azepines
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In silico driven GPCR drug discovery
Today, GPCR modelling is widely used in the structure-based
drug discovery process. The availability of structural informa-
tion on the binding site of a targeted GPCR plays a key role in
rationalisation, efficiency and cost-effectiveness of drug de-
sign. X-ray crystallography, a traditional source of structural
information, is not currently feasible for every GPCR or
GPCR-ligand complex. This situation significantly limits the
ability of crystallography to impact drug discovery for GPCR
targets in ‘real-time’ and hence there is an urgent need for
other practical alternatives. GPCR modelling is widely used
as a practical alternative in the absence of crystallographic
data, but can also provide much more useful information.
Today, it can address such key issues like GPCR flexibility
and dynamics, ligand kinetics (kon/koff rates), prediction of
water positions and their role in ligand binding, calculation
of the free energy of binding (affinity) and prediction of the
effects of mutations on ligand binding, etc. Some of these
modelling approaches were reviewed in this meeting.
The role of flexibility and dynamics in the development of
antipsychotic drugs and how this can be addressed by
computational approaches was discussed. Recent pharmaco-
logical studies revealed that clinically effective antipsychotic
agents act by binding to several bioamine receptors (Roth
et al. 2004). In particular, the interaction with the serotonin
(5-HT2A and 5-HT6) and dopamine (D2 and D3) receptors
(group 1) induces cognition-enhancing effects, while the his-
tamine (H1), 5-HT2C and 5-HT2B receptors (group 2) modu-
lation causes unwanted side effects (Selvam et al. 2013). Due
to the complex pharmacological profile of CNS disorders, the
attempts to develop drugs based on the one-target-one-disease
paradigm have been limited (Allen and Roth 2011). As a re-
sult, there remains an urgent need for innovative approaches to
develop new effective multi-target agents that improve pa-
tients’ health while reducing care costs. Ideal candidates
should selectively target disease-active members of the family
(group 1) while not binding to members responsible for un-
desired side effects (group 2). This is a very challenging goal
to achieve, as the residues forming the orthosteric binding
pocket, i.e. the binding site of endogenous ligands, are con-
served within the receptor family, thus causing the recognition
of a drug bymany members. A strategy to overcome this issue
is to design allosteric drugs targeting a less conserved alloste-
ric site, which modulates the orthosteric site, or to design
bitopic drugs, which bind to both allosteric and orthosteric
sites.
The recently released crystal structures of several bioamine
receptors in complex with orthosteric and allosteric ligands
enable the selectivity issue of antipsychotic drugs to be ad-
dressed at the molecular level. Thus, ‘structural snapshots’
provided by crystallography can be used to explore receptor
motions using computer simulations. It is conceivable that
allosteric and bitopic modulators interact with binding pockets
that exist only in a subset of the receptor conformational
space. Computer modelling can contribute to their identifica-
tion by providing detailed insights into motions and interac-
tions in the entire protein family and subsequently unravelling
Fig. 9 Homology model of the
CCR4 receptor, with putative
multiple binding sites for peptide
agonists and small molecule
allosteric ligands
Fig. 10 One of the low-energy conformations of the extended dual
H1H3R ligands docked into the homology model of H1
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complex relationships in generated data within a reasonable
time and at low cost. In academia, this approach has been
undertaken with some promising results. For example, in the
Tikhonova group, a computational protocol combining con-
cepts from statistical mechanics and chemoinformatics have
been developed to explore the flexibility of the bioamine re-
ceptors and identify geometrical and physicochemical proper-
ties that characterised the conformational space of the
bioamine receptor family (Selvam et al. 2013). Figure 11 il-
lustrates the molecular modelling steps undertaken to identify
the unique pharmacophoric features of disease-active
receptors.
The bioamine receptors of groups 1 and 2 have been sub-
jected to molecular dynamics simulations in a realistic envi-
ronment. The results of simulations show substantial flexibil-
ity and its variability across the members of the receptor fam-
ily. Using molecular probe mapping technique combined with
the volume-based Tanimoto similarity measurements, similar
and different geometrical and physicochemical properties
were shown across the conformational space of the receptor
family and the unique pharmacophoric features of disease-
active receptors (group 1) were highlighted. The unique fea-
tures are then linked with mutational and ligand structure-
activity relationship data and tested in retrospective screening.
The combination of techniques used gives an efficient method
to identify unique properties of the disease-related proteins on
the reduced diverse conformational space and represents a
novel application of existing computational methods for the
invest igat ion of s t ructural reasons for select ive
polypharmacology (Selvam et al. 2013). This protocol can
be now exploited by industry for other protein families, in-
volving in cancer and infectious diseases, which require a
multi-target approach.
In an industry setting, Evotec Ltd uses a hierarchical GPCR
modelling protocol (HGMP) that has been developed in con-
junction with the University of Oxford to support structure-
based drug discovery programs (see Fig. 12a) (Heifetz et al.
2013a, b). The HGMP generates a 3D model of GPCR struc-
tures and its complexes with small molecules by applying a set
of computational methods. The models produced by HGMP
are then used in structure-based drug discovery. HGMP in-
volves homology modelling, followed by MD simulation
and flexible ensemble docking, to predict binding poses and
function of ligands bound to GPCRs. The HGMP includes a
large set of unique plugins to refine the GPCR models and
exclusive scoring functions like the GPCR-likeness assess-
ment score (GLAS) to evaluate model quality (Heifetz et al.
2013a). HGMP is also ‘armed’ with a pairwise protein com-
parison method (ProS) used to cluster the structural data gen-
erated by the HGMP and to distinguish between different
Fig. 11 Structure-based computational protocol for selective polypharmacology—figure adapted from a recent publication (Selvam et al. 2013)
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activation sub-states. Recently, the capabilities of HGMP have
been extended by the addition of GPCR biased ligand tools.
The optimisation of HGMP has been performed by Evotec
Ltd in real drug discovery projects.
The performance of HGMP in GPCR drug discovery pro-
jects such as MCH-1R for obesity treatment (Heifetz et al.
2013a), the Orexin-1 and -2 receptors for insomnia (Heifetz
et al. 2012, 2013b) and the 5-HT2C for the treatment of met-
abolic disorders (Tye et al. 2011; Storer et al. 2014) (see
Fig. 12b) were highlighted. Additionally, the HGMP technol-
ogy was used in the solving of the two H1R crystals structures
bound to the second- and third-generation antihistamines:
Cetirizine (Gillard et al. 2002) and Fexofenadine (Sharma
et al. 2014), respectively, as described by Dr. Moraes (above).
Another area that has received increasing attention over
recent years has been the role of water networks and their
elucidation byMD simulations (Tautermann et al. 2015).With
the availability of more very high-resolution GPCR structures
[e.g. the δ-OR (Fenalti et al. 2014) or the A2AR (Liu et al.
2012) with resolutions of 1.8 Å], it has become clear that
GPCRs often exhibit conserved water networks, which extend
from the extracellular side to the intracellular surface. This
conserved solvent network has been implied to be crucial for
signalling (Nygaard et al. 2009) and a highly solvated con-
served allosteric sodium binding site close to the conserved
NPxxY motifs of class A GPCRs is postulated to be involved
in β-arrestin signalling (Fenalti et al. 2014; Tautermann
2014). Beyond the functional effects, the consideration of wa-
ter molecules in GPCR ligand design has been shown to be
crucial (Bortolato et al. 2013) because several crystal struc-
tures show water-mediated ligand-protein interactions (Con-
greve et al. 2014). The displacement of binding site water
upon ligand binding is energetically disadvantageous. There-
fore, a ligand always has to gain more free energy from bind-
ing to the receptor than the removal of water actually costs.
Several methods are available which enable the very crude
and quick estimation of the energy penalty for water displace-
ment, and most efficiently they are used for growing a bound
ligand (Bortolato et al. 2013). They can help medicinal chem-
ists to decide if a certain sub-pocket of the receptor can be
explored by hydrophobic moieties or if a displaced water has
to be substituted by an entity which has to mimic the hydrogen
bond network. Obviously, these quick methods are not thor-
ough in a sense that the estimates of the free energy are phys-
ically sound, but often they are sufficiently good for a go/no-
go decision. In order to get a (formally) correct estimate for the
change in the free energy of binding upon ligandmodification,
methods like thermodynamic integration have to be applied
(Christ and Fox 2014). These more accurate methods all rely
on long MD simulations of the receptor, and therefore they
Fig. 12 a HGMP workflow and
b a model of 5-HT2C (in red)
produced by the HGMP
workflow. The ligand is shown in
green and the whole complex
(Tye et al. 2011) is embedded in a
membrane (grey). The water
molecules and ions are omitted
from the figure for clarity
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can also capture reorganisations in the solvent network and
induced effects in the binding pocket. One step further beyond
assessing the free energy of ligand binding is the estimation of
binding kinetics of ligands. Water networks also play a crucial
role here as well, as the breaking of ligand-receptor hydrogen
bonds usually ends up with solvated hydrogen bond acceptor
and donor functional groups. As the energy barrier of the
reaction determines the rate constant, the direct interaction of
water molecules with the ligand-protein hydrogen bonds is
decisive for the dissociation rate. If the hydrogen bond is
solvent accessible, the breaking of the bond does not require
high energy because the re-hydration occurs simultaneously.
If the hydrogen bond is buried, a breaking leads to a high
energy penalty because acceptor and donor do not find imme-
diate new interaction partners and are in unfavourable solva-
tion states (Schmidtke et al. 2011). Currently, the in silico
prediction of association/dissociation rates is only possible
for very small fragments rather than drug-like molecules.
Therefore, the state-of-the-art is still the explanation of ex-
perimental off-rates of drug-like molecules rather than the
prediction of them. Recently, the duration of action of
tiotropium on the human muscarinic M3 receptor (hM3R)
was studied (Tautermann et al. 2013). Substitution of the
hydroxy-group (see Fig. 13) by methyl does not reduce the
pKi strongly, but it has a major effect on the receptor half-life
of the molecule. Long MD simulations (>2 μs) were used to
investigate the differences in the bound species, especially
focussing on the water network. Tiotropium forms a double
hydrogen bond to N6.52 in hM3R (Fig. 13, left panel), and
during the simulation no water comes close (blue solid sur-
face). When substituting the hydroxy-group by methyl
(‘methyl ligand’), water density is observed directly above
the (single) hydrogen bond (green mesh), corresponding to a
large number of MD snapshots where N6.52 is (partly) sol-
vated. This comes along with a significantly widened exit
channel of hM3R, and some MD snapshots even show water
inserting in the hydrogen bond, as displayed in Fig. 13 (lower
right panel). Thus, the explanation for the unexpected change
in off-rates is the fact that the shielded hydrogen bond in
bound tiotropium becomes solvent exposed when modifying
the ligand. This observation was only possible through long
MD simulations, and an explanation by the static x-ray struc-
ture would not have been possible. To summarise, the deep
understanding of water networks within GPCRs has proven to
be essential if one wants to understand GPCR signalling as
well as GPCR ligand binding and dissociation. MD simula-
tions are a very valuable tool to derive physically meaningful
parameters such as free energy differences or solvent maps
Fig. 13 Left—comparison of the water (oxygen) densities in the
tiotropium and the methyl ligand. The water densities of the tiotropium
MD are displayed as blue solid surfaces; densities in methyl-ligand MDs
are shown as green mesh. The significant extra density in the methyl-
ligandMD is marked by a green ellipse. Top right—chemical structure of
tiotropium (R=OH) and the methyl-ligand (R=CH3). Middle right—
binding and dissociation constants of the ligands at the hM3R. Bottom
right—a snapshot of the MD simulation with the methyl ligand, where
water inserts into the ligand-protein hydrogen bond (in contrast to the
tiotropium MD, where such water-mediated hydrogen bonds are never
observed)—figure adapted from the recent publication (Tautermann et al.
2015)
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because they capture the dynamics of the systems, which is
crucial especially for flexible proteins such as GPCRs.
An essential part of computational modelling is to re-
evaluate predictions often in light of new structural data. Re-
searchers at Novartis Horsham had performed a large amount
of work exploring the binding sites of allosteric inhibitors of
the chemokine receptor CXCR2, and several interesting things
emerged after re-analysing this work in the light of crystallo-
graphic data (Salchow et al. 2010). It had been determined at
Novartis Horsham that antagonists were acting at an allosteric
binding site, and the patent literature around the time of the
work suggested that the CXC chemokines could have a bind-
ing site close to the intracellular face of the receptor. One of
the key residues in this binding site was proposed to be K320
as the CXCR2 antagonists commonly had an acidic function-
ality of some description within them and this residue was
asparagine in the related CXCR1 receptor over which many
of the CXCR2 antagonists had selectivity.
The mutagenesis experiments that were undertaken did
show that residues at the intracellular end of the TM domains
had an influence on the binding and/or potency of the antag-
onists whilst one proposed as critical within the TM domain
did not show any influence. However, the expected overlay of
the antagonists based upon their ligand-only overlays was not
reproduced in the effects seen against the various mutant re-
ceptors. The presumed binding modes derived from this work
are shown in Fig. 14a. The residues proposed for mutagenesis,
and the interpretation of their effects, were very dependent
upon the model used to create the homology model for
CXCR2 at the time, and so a review of how the latest GPCR
crystal structures could have influenced this project was
presented.
The NMR structures for the related CXCR1 receptor (as
reproduced in Fig. 14b) consistently show that the critical
N320 residue is not close to the other influential residues,
and it would have been hard to rationalise the mutagenesis
from this template. The CCR5 crystal structure shows distor-
tion in the TM7/helix 8 region and the critical K320 residue
was mutated to a GLU, but overall the helical alignment com-
pared to Rhodopsin was very similar and so would not have
provided any benefit compared to the Rhodopsin template
used originally. The β2AR-Gs-protein structure was a marvel-
lous achievement (Rasmussen et al. 2011), but for the pur-
poses of acting as a template for the intracellular binding area
of the antagonists, it is likely to be too different to CXCR2 to
be useful. The most relevant structure could have been the
CXCR4, but here again the TM7/helix 8 region is distorted
in the crystal and a CXCR2 homology model was created by
using a chimeric template of this receptor and the TM7/helix 8
region from an earlier β2AR structure (Rasmussen et al.
2011). Interestingly, this model had a related CXCR2 antago-
nist bound in the TM domain and the major learning point
from the current GPCR symposium was just how much influ-
ence changes within the TM domain affected the intracellular
coupling and vice versa. A conclusion drawn from the sym-
posium with respect to the work completed at NIBR Horsham
would be that more mutagenesis information from across the
whole of the CXCR2 protein would have been needed in order
to fully understand the binding area of these allosteric
antagonists.
Finally, network-based approaches, evolutionary algo-
rithms and predictive modelling, all areas that will become
more prevalent in the future, were discussed. The advent of
the ‘omics’ age has brought with it huge quantities of data
around diseases, targets, compounds and their effects. Net-
works of interactions and disease ‘interactomes’ can be built
with the ultimate goal to understand disease networks and
how they are influenced by the changes in small molecules
and their properties.
The polypharmacology associated with current typical and
atypical anti-psychotics is complex, and as an example, the
question of how do we go about designing a novel anti-
Fig. 14 a The proposed binding modes for the quinoxaline (yellow
carbons) and urea (cyan carbons) series with the influential mutated
residues in CXCR2 shown in CPK. The consistent influence of K320
locates the acidic functionality in the antagonists, yet the varying effects
of D143 on representatives of these two series suggest that the
hydrophobic groups are located differently. b Overlay of the CXCR1
NMR structures from the PDB (code 2LNL) N320 is shown in green
CPK and influential mutants from our experiments in purple CPK. The
protein backbones, in ribbon representation, are coloured fromN (blue) to
C (red) termini
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psychotic given the tools and data we have access to today
wa s r a i s e d . T h e o p e n s o u r c e ChEMBL sp a c e
polypharmacology network viewer (Fechner et al. 2013) was
introduced as an interactive way to review the rich pharma-
cology accessible in the ChEMBL database and identify some
good starting points for drug design. The experimental
polypharmacology associated with the hits can be
complemented using target prediction ligand similarity-
based approaches such as the similarity ensemble approach
(SEA; Keiser et al. 2009) or broad panel-based predictive
modelling approaches (Ghosh and Jones 2014). Predictive
modelling approaches were also used to build protein target
QSARs that in combination with pharmacophore triplet com-
pound similarity were used to develop a multi-objective scor-
ing function. Given a small organic fragment, an automated
evolutionary design algorithm using reaction vectors was used
to grow a molecule by simultaneously optimising the multi-
parameters requi red for the targe ted phenotype
polypharmacology (Patel et al. 2009) (see Fig. 15). The reac-
tion vector design approach was extended to whole reaction
sequences and ultimately reaction networks. A GPR38 reac-
tion network was built which exemplified that the chemistry
phase space around a hit could be readily expanded to that of
closely accessible molecules. This would enable better sam-
pling and rapid medchem design.
It was also shown how GPCR targets and their interacting
partners could be identified from Genome Wide Association
Studies (GWAS) using network analysis followed by the anal-
ysis of compound gene expression data to complement target
disease gene expression as a strategy for network-based drug
design. Multiple algorithms have been developed that in
combination with omics data and GPCR structure-based de-
sign make a powerful arsenal for today’s drug designer.
Conclusions
All participants agreed that GPCR research and drug discov-
ery can benefit greatly from the collaboration between acade-
mia and industry. The effectiveness of such collaborations for
GPCR research and drug discovery was widely described and
exemplified during this conference: the non-profit GPCR
Consortium (http://gpcrconsortium.org) described by Vadim
Cherezov; the collaboration between MRC Laboratory and
Heptares mentioned by Gebhard Schertler and Chris Tate;
the consortium between Evotec Ltd, Oxford University UK
and the Membrane Protein Laboratory at Diamond Light
Source, UK described by Alexander Heifetz; and many
other successful networks like the Adhesion-GPCR Consor-
tium (AGC) or GLISTEN (Gutierrez-de-Teran 2014) (GPCR-
Ligand Interactions, Structures, and Transmembrane Signal-
ling: a European Research Network).
There was broad agreement with Schertler’s and Ceska’s
comments that most ventures between academia and industry
are dependent on track record and trust and that individuals
have to commit to a longer-term perspective which is aimed at
changing the scientific landscape. There was also agreement
that meetings between academia and industry such as this
conference are very useful to learn about developments within
each other’s areas of expertise and to share the challenges
whilst forging new links and networks. For future meetings
of this type, it was proposed to also include a broader mix of
Fig. 15 Automated multi-objective compound design using reaction
vectors (26K Reaction Db and 93K Reagents) starting from piperidine
and using four objectives: similarity to haloperidol and Ziprasidone
pharmacophores, Dopamine D2, α1B Adrenergic and Histamine QSAR
models. The tri-cyclics generated appeared similar to known anti-
pyschotics, Chlorpromazine and Fluphenazine
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younger-generation scientists early in their career in order to
maximise benefit to a broader community.
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